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Abstract
To date, there is no definite effective treatment for the COVID-
19 pandemic. We performed an update network meta-analysis to
compare and rank COVID-19 treatments according to their efficacy
and safety. Literature search was performed from MEDLINE and
CENTRAL databases from inception to September 5, 2020.
Randomized clinical trials (RCTs) which compared the effect of any
pharmacological drugs versus standard care or placebo 28-day after
hospitalization in adult patients with COVID-19 disease were
included. Risk ratio (RR) and 95% CI were calculated for 28-day
all-cause mortality, clinical improvement, any adverse event (AEs),
and viral clearance. A total of 25 RCTs, evaluating 17 different treat-
ments, and 11,597 participants were analyzed. Remdesivir for 10-
day compared to standard care (RR 0.69, 95% CI [0.48–0.99]), and
a low dose compared to a high dose of HCQ (0.38, [0.17–0.89])
were associated with a lower risk of death. A total of 2,766 patients
experienced clinical improvement, a 5-day course of remdesivir
was associated with a higher frequency of clinical improvement
compared to standard care (RR 1.21, 95% CI [1.00–1.47]).
Compared to standard care, remdesivir for both 5 and 10 days,
lopinavir/ritonavir, and dexamethasone reduced the risk of any
severe AEs by 52% (0.48, 0.34–0.67), 24% (0.77, 0.63–0.92), 40%
(0.60, 0.37–0.98), and 50% (0.50, 0.25–0.98) respectively. In this
study of hospitalized patients with COVID-19, administration of
remdesivir for 10-day compared to standard care was associated
with lower 28-day all-cause mortality and serious AEs, and higher
clinical improvement rate.  
Introduction
Despite more than 28 million cases and 900,000 deaths in
early September caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) pandemic, no definite effective
treatment is available.1 The urgency of this situation accelerated
randomized trials of many repurposed drugs that had been shown
to be effective in vitro or in or the therapeutic experience with
SARS-CoV-1, and Middle East respiratory syndrome (MERS)-
CoV infection.2
In this context, numerous meta-analyzes were quickly carried
out, in particular on the efficacy of hydroxychloroquine (HCQ).
Data from Million et al.3 indicated the effectiveness of HCQ in
reducing mortality in COVID-19 disease, while those of Singh et
al.4 and Fiolet et al.5 concluded that HCQ was ineffective.
A recent prospective meta-analysis of seven clinical trials
involving 1,703 critically ill patients with COVID-19 reported the
benefit of routine administration of corticosteroids, compared
with usual care or placebo, in to reducing 28-day all-cause mortal-
ity based only on the fixed-effect model.6 Overall, routine admin-
istration of corticosteroids is associated with a 34% reduction in
mortality (summary OR, 0.66 [95%CI, 0.53-0.82]), and among
corticosteroid drugs, only dexamethasone was beneficial (0.64
[0.50-0.82]). In the subgroup analysis, the greatest benefit of sys-
tematic corticosteroids was observed in patients who were not
receiving vasoactive drugs (0.55 [0.34-0.88]) or invasive mechan-
ical ventilation at randomization (0.41 [0.19-0.88]).  
As there is no recommended treatment or vaccine to contain
the disease to date, identifying the most effective treatment is an
urgent medical need. To summarize data on promising treatments
against COVID-19, we conducted a preliminary network meta-
analysis (NMA) based on 14 randomized controlled trials (RCTs)
evaluating 11 different treatments among 2,898 patients.7
Systematic Reviews and Meta-Analysis
Significance for public health
The current COVID-19 pandemic is the largest and deadliest coronavirus pandemic in history, leading to considerable global public health problems. To date
more than 28 million cases and 900,000 deaths have been reported. This is an update of our previous systematic review and network meta-analysis to compare
and rank COVID-19 treatments. Available data indicate that in hospitalized patients with SARS-CoV-2 infection, administration of remdesivir compared to
standard care and low dose of HCQ compared to high dose were associated with lower risk of 28-day all-cause mortality. In the absence of compelling con-
traindication, a remdesivir regimen should be part of standard care for inpatients with COVID-19.
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We found no difference between treatments in terms of
reduced 28-day all-cause mortality. The aim of this update network
meta-analysis of randomized trials was to compare and rank the
efficacy and safety of treatments tested in patients with SARS-
CoV-2 virus.
Design and Methods
Search strategy and selection criteria
In our previous report,7 search through MEDLINE and
Cochrane library (CENTRAL) was performed from inception to
June 30, 2020 and it identified 14 RCTs published in any language.
Then, from July 1 to September 5, 2020, 11 additional RCTs were
found and included in the current updated network meta-analysis.
Data were collected as studies were identified; the latest date for
this search was September 5, 2020. We included RCTs that com-
pared in adult patients with COVID-19 (P) any pharmacologic
drug (I) versus standard care or placebo (C) to evaluate both effi-
cacy (mortality, clinical improvement, viral clearance) and safety
(adverse event and serious adverse event) (O) 28-day (T) after hos-
pitalization (S). Trials in which participant were non-randomly
assigned to SARS-CoV-2 treatment were excluded. Using the
search terms listed in the Supplementary Method, AD and MT
identified all relevant studies, then independently reviewed their
full texts, and in case of disagreement, differences were resolved
through arbitration by another author (MCB). Extracted data
included: first author name and year of publication, country, RCTs
design, study follow-up, age (mean), proportion of male partici-
pants, treatment and dosing information, sample size, study spon-
sorship, proportion or number of participants with clinical
improvement, all-cause mortality, and adverse events. The study
protocol number is CRD42020176977 (PROSPERO).
Treatments exposure
We considered any pharmacological drugs tested to evaluate
their efficacy and safety in patients infected with SARS-CoV-2.
For randomized trials, patients were defined as receiving interven-
tion or control if they were randomly allocated to receive either
treatment. Almost all patients received supportive care according
to the standard care at the trial site.
Primary and secondary outcomes
The primary outcome was 28-day all-cause mortality.
Secondary outcomes were clinical improvement within 28-day
after randomization, any reported Adverse Events (AEs), severe
AEs, and viral clearance rate (negative conversion rate). Clinical
improvement was defined as patient discharge or a reduction of 2
points on a 7-point disease severity scale. As these secondary out-
comes were evaluated at different time-points across studies, we
chose to consider only the latest in each trial.
Data analysis
The original clinical trials were described using summary table
of study characteristics and forest plot. The Revised tool for Risk
of Bias in randomized trials (Rob2 tool)8 was used to assess the
risk of bias and to generate its number? We opted for a frequentist
approach to compare the efficacy and safety of the treatments test-
ed using a random-effects network meta-analysis (NMA) for bina-
ry endpoint. Summary estimates were reported as risk ratio (RR)
with their reported 95% confidence intervals. For clinical improve-
ment and decreased viral load, beneficial effects are described by
RRs >1, while for 28-day mortality and AEs, beneficial effects are
described by RRs <1. To display the relative efficacy and safety
outcomes of all available pairwise comparisons between treat-
ments, league tables were used. To choose the preferred regimen,
the P-score ranging from 0 (worse treatment) to 1 (best treatment)
was computed for each treatment, then the treatment with a higher
P-score was selected as better than the competing treatment.
Heterogeneity and inconsistency were quantified using the global
Q test proposed by Rucker.9 The Q statistic is the sum of statistic
for heterogeneity, which represent the proportion of total variation
in study estimates (within-designs), and a statistic for inconsisten-
cy (between-designs), which represents the variability of treatment
effect between direct and indirect comparisons at the meta-analytic
level. To visualize and identify the nodes of single-design inconsis-
tency, we used a network heat plot. Consistency between direct and
indirect comparisons was checked using the so-called node-split-
ting. To confirm or deny the effect of any corticosteroid on 28-day
all-cause mortality reported in the WHO prospective meta-analy-
sis,6 we performed one non-prespecified sensitivity analysis by
considering any routine corticosteroid as a single treatment (com-
bining dexamethasone, hydrocortisone and methylprednisolone).
All analyses were performed using R package ‘netmeta’;9 P-values




The initial search through all database identified 1,042 cita-
tions, of which 402 were screened by title and abstract after remov-
ing duplicates. Of 38 full-text citations reviewed, 25 RCTs6,10-31
that met the inclusion criteria were finally included in the quanti-
tative network meta-analysis (Figure 1). These 25 RCTs (two
phase 2 and five blinded) included a total of 11,597 patients infect-
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Figure 1. PRISMA flowchart of studies selected for meta-analysis










ed by the SARS-CoV-2 with mean ages ranging from 29.7 to 70
years; 7,363 (62.3%) were men; they were followed for 6 to 28
days (Table 1). Comorbidities were present in 4,579 (39.0%)
patients, the most common being diabetes (2,818; 24.0%) and
hypertension (1,761; 15.0%). 
The methodological quality of included RCTs is shown in
Supplementary Figures 1 and 2. Overall, the risk of bias was low
in nine RCTs, moderate in four, and high in the remaining RCT. A
higher risk of attrition bias (incomplete outcome data), perform-
ance bias (blinding participants and personnel), and selection bias
(allocation concealment) occurred in 6, 6, and 1 of the 25 RCTs,
respectively.
All-cause mortality within 28 day
All-cause mortality data were reported in 18 trials involving 14
treatments and 22 comparisons. A total of 2,228/10,880 (20.4%)
patients died within 28 days of randomization, and ruxolitinib (5
mg twice a day) was ranked as the best option with an 83% prob-
ability (P-score 0.83) to be associated with a lower risk of death.
Compared to standard care, remdesivir for 10 day reduced the risk
of death by 31% (risk ratio (RR) 0.69, [0.48-0.99]). In addition, a
low dose of HCQ reduced by 62% (0.38, [0.17-0.89]) the risk of
death compared with a high dose of HCQ. No significant differ-
ence was observed between the other comparisons (Figure 3;
Supplementary Table 1). Likewise, no significant differences were
found between direct and indirect comparisons of treatment esti-
mates or evidence of publication bias according to the comparison-
adjusted funnel plot (Supplementary Figures 3 and 4). 
Clinical improvement
Clinical improvement data were reported in 17 trials involving
13 treatments and 23 comparisons. Among the 4,317 participants
in whom clinical status was evaluated, 2,766 (64.1%) experienced
clinical improvement within 28 days after randomization.
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Figure 2. Network graph of eligible SARS-CoV-2 treatments com-
parisons for any adverse event. Line width is proportional to the
number of trials comparing every pair of treatment. The size of
the circle is proportional to the number of participants assigned
to receive the treatment; Remdesivir (5-day), remdesivir for 5-
day; remdesivir (10-day), remdesivir for 10-day; Plasma, conva-
lescent plasma; HCQ, hydroxychloroquine; Kaletra,
lopinavir/ritonavir.
Figure 3. Network meta-analysis comparing single treatment with
standard of care of SARS-CoV-2 outcomes. Blue, clinical
improvement; black, any adverse event; magenta, any serious
adverse event; red, all-cause mortality; green, viral clearance rate.
Treatments are ordered in the rank of their chance of being the
best option. Treatment estimates are provided as risk ratios (RR)
with 95% CIs. RRs >1 indicates a beneficial treatment effects
compared to standard care (clinical improvement and viral clear-
ance lead), while RRs >1 is favor for standard care (any AEs or
serious AEs and mortality); RDVs, remdesivir for 5-day; RDV,
remdesivir more than 5-day; FPV, favipiravir; LPVRTV,
lopinavir/ritonavir; LPVRTVRBV, lopinavir/ritonavir and rib-
avirin; ARB, arbidol (umafenovir). Plasma, convalescent plasma;
StdCare, standard of care; AZT, azithromycin; HCQlow, low dose
of hydroxychloroquine (450 mg); HCQ, hydroxychloroquine;
HCQAZT, association hydroxychloroquine and azithromycin;
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Table 1. Characteristics of 25 included trials investigating efficacy and safety of SARS-Cov-2 disease.                              
Study               Location           Design             Age       Follow-            Total          Randomized treatments                                           Main primary                                   Sponsorship          Risk of
                                                                        (mean,       up         participants     in each group,                                                           endpoints                                                                          bias
                                                                        years)     (days)       (proportion     dosing information                                                                                                                                             (Rob2)
                                                                                                              of men)        
Chen Jun                   China               Open-label,        46.7 – 50.5         15                   30 (70%)           400 mg hydroxychloroquine                                                         Negative conversion rate                             NR                                    Some 
et al.11                                                          RCT                                                                                               (HCQ) orally for times daily for 5 days;                                   of SARS-CoV-2 nucleic acid                                                                concerns
                                                                                                                                                                           Standard of care (bed rest, oxygen                                           in respiratory pharyngeal 
                                                                                                                                                                           inhalation, antiviral drugs as lopinavir/                                      swab on days 7 
                                                                                                                                                                           ritonavir, and antibacterial drugs                                               after randomization.
                                                                                                                                                                           if necessary)
Li Ling                        China               Open-label,               70                28                102 (58.3%)         4 to 13 ml/kg Convalescent plasma transfusion;                     Time-to-clinical improvement                    CIFMS                         Hight risk 
et al.15                                                        RCT                                                                                               Standard of care (antiviral, antibacterial                                 within a 28-day period;                                                                          of bias
                                                                                                                                                                           medications, steroids, human immunoglobulin,                    clinical improvement was defined 
                                                                                                                                                                           Chinese herbal medicines)                                                         as patient discharge or a reduction
                                                                                                                                                                                                                                                                                        of 2 points on a 6-point disease 
                                                                                                                                                                                                                                                                                        severity scale.a
Cao                             China               Open-label,               58b                28               199 (60.3%)         400 mg and 100 mg of the oral combination                             Time-to-clinical improvement within        Major Projects of     Hight risk 
et al.18                                                          RCT                                                                                               lopinavir/ritonavir respectively twice a day                              a 28-day period, defined as time from      national Science           of bias
                                                                                                                                                                           for 14 days; Standard of care (supplemental                          randomization to either                               and Technology
                                                                                                                                                                           oxygen, noninvasive and invasive ventilation,                          an improvement of two points on              on NDCD
                                                                                                                                                                           antibiotic agents, vasopressor support,                                   a seven-category
                                                                                                                                                                           renal-replacement therapy, and ECMO)                                  ordinal scale,a or discharge
                                                                                                                                                                                                                                                                                        from the hospital,
                                                                                                                                                                                                                                                                                        whichever came first.
Wang                          China                      RCT,                     65b                28               237 (59.1%)         200 mg on day 1 and 100 mg on days                                          Time-to-clinical improvement                    CAMSEP of                 Hight risk 
et al.19                                                           double-blind                                                                                       2 to 10 in single daily infusions                                                   within a 28-day period,                                 Covid-19,                         of bias
                                                                                                                                                                           of Remdesivir;  placebo                                                                defined as time from                                    NKRDPC,
                                                                                                                                                                                                                                                                                        randomization to either an                         and BSTP
                                                                                                                                                                                                                                                                                        improvement of two points 
                                                                                                                                                                                                                                                                                        on a seven-category ordinal scale,a
                                                                                                                                                                                                                                                                                        or discharge from the hospital, 
                                                                                                                                                                                                                                                                                        whichever came first.
Borba Silva                Brazil                      RCT,                     51.1               28                 81 (75.3%)          600 mg hydroxychloroquine (HCQ)                                           Lethality by at least 50%                               Government of         Low risk 
et al.20                                                    phase IIb,                                                                                        or high-dose orally or via nasogastric                                       in the high-dose group                                 the Amazonas            of bias
                                                             double-blind                                                                                       tube (4×150 mg tablets twice daily                                           compared with the low-dose                      State
                                                                                                                                                                           for 10 days; total dose 12 g);                                                       group at day 28.
                                                                                                                                                                           450 mg HCQ or low-dose (3×150 mg 
                                                                                                                                                                           tablets and 1 placebo tablet twice 
                                                                                                                                                                           daily on day 0, 3×150 mg tablets and 1 
                                                                                                                                                                           placebo tablet once a day followed 
                                                                                                                                                                           by 4 placebo tablets from day 1 to day 4, 
                                                                                                                                                                           then 4 placebo tablets twice daily from 
                                                                                                                                                                           day 5 to day 9; total dose 2.7 g)
Goldman                   US,               Open-label,             62b               28              397 (63.7%)        200 mg of remdesivir on day 1 followed                             Clinical status on day 14,                         Gilead Sciences      Hight risk 
et al.16                              Italy,                     RCT                                                                                         by 100 mg  of remdesivir once daily for                               assessed on a 7-point                                                                     of bias
                                          Spain,                                                                                                                    subsequent 4 or 9 days.                                                          ordinal scale.a
                               Germany,                                                                                                                                               All group receive a standard of care 
                             Hong Kong,                                                                                                                therapy according to the local guidelines. 
                             Singapore,                                                                                                                 5-day group and 10-day group.
                            South Korea 
                                 Taiwan 
Li Yueping              China              Exploratory             49.4              21               86 (46.5%)        200 mg of lopinavir boosted by 50 mg                                 Time of positive-to-negative                   IDSG; High-level      Low risk 
et al.14                                                                  RCT,                                                                                        of ritonavir (orally administered, twice                              conversion of SARS-CoV-2                       Clinical Key                of bias
                                                         double-blind                                                                                 daily 500 mg each time for 7-14 days;                                   nucleic acid from the                               Specialty 
                                                                                                                                                                  n=34); 100 mg of arbidol (orally                                         initiation of treatment to day 21.           (2019-2021)
                                                                                                                                                                  administered, twice daily 200 mg 
                                                                                                                                                                  three times for 7-14 days; n=35); 
                                                                                                                                                                  Control group (n=17) 
Chen                        China                RCT, 44.7                  6         62 (46.8%)                                    400 mg hydroxychloroquine                                                   Time-to-clinical recovery (TTCR)          Science and                 Some 
et al.12                                              double-blind                                                                                 (HCQ) per day orally between days 1 and 5;                      at 5 days, defined as the return             Technology               concerns
                                                                                                                                                                  Standard of care (oxygen therapy, antiviral                       of body temperature and cough            Department of 
                                                                                                                                                                  agents, antibiotic agents, and immunoglobulin,               relief maintained for                                Hubei Province 
                                                                                                                                                                  with or without corticosteroids)                                          more than 72 h.                                          (2020FCA005)
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Table 1. Continued from previous page.      
Study               Location           Design             Age       Follow-            Total          Randomized treatments                                           Main primary                                   Sponsorship          Risk of
                                                                        (mean,       up         participants     in each group,                                                           endpoints                                                                          bias
                                                                        years)     (days)       (proportion     dosing information                                                                                                                                             (Rob2)
                                                                                                              of men)        
Tang                         China             Open-label,              46                28               150 (55%)         1200 mg hydroxychloroquine (HCQ)                                   Negative conversion of                            Emergent Projects Hight risk 
et al.17                                                      RCT                                                                                         daily for three days followed                                                 SARS-CoV-2 by 28 days.                             of National                  of bias
                                                                                                                                                                  by a maintenance dose of 800 mg daily                                                                                                     Science and 
                                                                                                                                                                  for the remaining days (two weeks for                                                                                                     technology
                                                                                                                                                                  patients with mild to moderate disease                                                                                                    (2020YFCO844500)          
                                                                                                                                                                  and three weeks for those with severe 
                                                                                                                                                                  disease); Standard of care
Chen                         China             Open-label,            29.7c              7               240 (46.6%)        1600 mg of favipiravir twice                                                    Clinical recovery rate at 7 days              NKRDPC                   Hight risk 
et al.13                                                      RCT                                                                                         first day followed by 600 mg, twice daily,                           from beginning of treatment,                (2020YFC0844400)     of bias
                                                                                                                                                                  for the following days;                                                            defined as continuous (>72 h) 
                                                                                                                                                                  200 mg of arbidol, three times daily                                     recovery of body temperature,
                                                                                                                                                                  plus Standard of care                                                              respiratory rate, oxygen saturation 
                                                                                                                                                                                                                                                                        and cough relief after treatment, 
                                                                                                                                                                                                                                                                        with following quantitative criteria: 
                                                                                                                                                                                                                                                                        axillary temperature 36.6°C, 
                                                                                                                                                                                                                                                                        respiratory frequency 24 times/min,
                                                                                                                                                                                                                                                                        oxygen saturation 98% without oxygen 
                                                                                                                                                                                                                                                                        inhalation; mild or no cough.
Hung                   Hong Kong         Open-label              52b               14                127 (54%)         400 mg of lopinavir and 100 mg                                             Time to providing a                                   Shaw-Foundation,  Hight risk 
et al.21                                             phase 2, RCT                                                                                 of ritonavir every 12 h, 400 mg                                               nasopharyngeal swab negative              Richard and                of bias
                                                                                                                                                                  of ribavirin every 12 h, 8 million                                          for SARS-CoV-2 by 7 days.                        Carol Yu, May Tam           
                                                                                                                                                                  international units of interferon                                                                                                                 Mark Mei Yin,                  
                                                                                                                                                                  beta-1b on alternate days for 14 days;                                                                                                       and Sanming 
                                                                                                                                                                  400 mg of lopinavir and 100 mg of ritonavir                                                                                              Project of 
                                                                                                                                                                  every 12 h for 14 days                                                                                                                                     Medicine                            
Deftereos             Greece            Open-label,              64b               21              110 (58.1%)        1.5 mg of colchicine followed by                                          Time from baseline                                   ELPEN, Acarpia,     Hight risk 
et al.31                                                     RCT                                                                                         0.5 mg 60 min later and maintenance                                  to-clinical deterioration,                         and  Karian                 of bias
                                                                                                                                                                  doses of 0.5 mg twice daily;                                                   defined as a grade increase                  Pharmaceuticals 
                                                                                                                                                                  Standard of care (optimal medical treatment                  on an ordinal clinical scale.a                       companies
                                                                                                                                                                  according to local protocols, as established 
                                                                                                                                                                  by the National Public Health Organization 
                                                                                                                                                                  and following the guideline of the European 
                                                                                                                                                                  Centre for Disease Prevention and Control)
Huang                      China                    RCT,                     44                14               22 (59.1%)         500 mg of chloroquine orally twice daily for 10 days;       Viral negative-transforming                    NR                                  Some 
et al.10                                                  phase 2,                                                                                     400 mg of lopinavir and 100 mg of ritonavir                       time and the negative                                                                   concerns
                                                         double-blind                                                                                 orally twice daily for 10 days;                                                 conversion rate of SARS-CoV-2
                                                                                                                                                                                                                                                                        RT-PCR  at day 10, 14.
Beigel                        US,                      RCT,                   58.9              25             1,059 (64.3%)      200 mg on day 1, followed 100 mg daily for                         Time-to-recovery, defined                      National Institute   Hight risk 
et al.24                              UK,             double-blind                                                                                 up to 9 additional days in single daily                                  as the first day,                                          of  Allergy                   of bias
                              Denmark,                                                                                                                 infusions of remdesivir;                                                         during the 28 days                                    and Infectious 
                                Greece,                                                                                                                   Placebo                                                                                       after enrollment,                                       Disease                              
                              Germany,                                                                                                                                                                                                                        on which a patient 
                                 Korea,                                                                                                                                                                                                                           satisfied category
                                Mexico,                                                                                                                                                                                                                          1, 2, or 3 on the
                                  Spain,                                                                                                                                                                                                                           eight-category scale.a
                                 Japan, 
                              Singapore                    
Cavalcanti               Brazil              Open-label,            50.3              15              665 (58.3%)        400 mg of HCQ twice daily for 7 days (n=221);                 Clinical status at 15 days using              Coalition                   Hight risk 
et al.22                                                      RCT                                                                                         400 mg of HCQ twice daily for 7 days plus                         the seven-level ordinal scale.                 COVID-19 Brazil        of bias
                                                                                                                                                                  azithromycin at dose of 500 mg once a day                                                                                               and EMS                            
                                                                                                                                                                  for 7 days (n=217); Standard of care (n=227)                                                                                         Pharma
Spinner                      US                Open-label,              57                28              596 (61.1%)        200 mg of remdesivir intravenously                                     The distribution of clinical status         Gilead Sciences      Hight risk 
et al.25                                                     RCT                                                                                         on day 1, followed by 100 mg                                                 assessed on the 7-point ordinal                                                  of bias
                                                                                                                                                                  of remdesivir for 5-day;                                                           scale on study day 11.
                                                                                                                                                                  200 mg of remdesivir intravenously on day 1, 
                                                                                                                                                                  followed by 100 mg of remdesivir for 10-day;
                                                                                                                                                                  Standard of care
Cao                         Wuhan,                   RCT,                     63                21               41 (58.5%)         5 mg of ruxolitinib orally twice a day;                                   Time-to-improvement defined              NR                               Low risk 
et al.23                      China                phase 2,                                                                                     Standard of care                                                                       as the time from randomization                                                   of bias
                                                          single-blind                                                                                                                                                                                        to an  improvement of 2 points on a
                                                                                                                                                                                                                                                                        7-category ordinal scale or live 
                                                                                                                                                                                                                                                                        discharge  from the hospital  at 14-day.                                            
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Treatment with Ruxolitinib 5 mg twice daily was ranked with a
high probability of clinical improvement at 28 days (P-score 0.78)
to be the best one. Except between remdesivir and standard care,
no significance differences between treatments were found from
pairwise comparisons (Figure 3 and Supplementary Table 2). RR
for remdesivir 100 mg once daily for 5 days compared with stan-
dard care was 1.21 (95% CI 1.00-1.47).
Viral clearance rate (negative conversion rate)
Viral clearance rate was assessed in 710,11,14,15,17-19 RCTs
involving 6 treatments and 9 comparisons. The use of convalescent
plasma was associated with higher viral clearance rate (P-score
1.00) compared to arbidol, standard care, HCQ, lopinavir/ritonavir,
and 10-day remdesivir. The corresponding increasing viral clear-
ance rate for convalescent plasma was 2.49 (1.53-4.05) compared
to arbidol, 2.68 (1.71-4.20) compared to standard care (Figure 3),
2.70 (1.69-4.30) compared to HCQ, 2.74 (1.72-4.39) compared to
lopinavir/ritonavir, and 2.87 (1.76-4.68) compared to 10-day of
remdesivir. The remaining comparisons were similar between
treatments (Supplementary Table 3).
Any adverse events
Concerning safety outcomes, the network meta-analysis was
performed in 21 RCTs, involving 17 treatments and 27 compar-
isons. Figure 2 shows the network for adverse event captured by
the SARS-CoV-2 treatment, and the corresponding pairwise com-
parisons are summarized in Supplementary Table 4. A total of
1,828/5,077 (36.0%) adverse events were reported at the end of
treatment. Dexamethasone was ranked as the best option with a
probability of 90% (P-score 0.90) of being associated with a lower
risk of any AEs. Except the use of convalescent plasma and the
association HCQ plus azithromycin (HCQ+AZT), the remaining
treatments were significantly associated with a lower risk of any
AEs as compared to colchicine (Supplementary Table 4). The cor-
responding risk reductions ranged from 48% to 82%. In addition,
we found that dexamethasone, arbidol, low dose of HCQ (400 mg),
and standard care (Figure 3) reduced the risk of any AEs by 66%
(0.34, 0.13-0.88), 62% (0.38, 0.14-1.00), 50% (0.30, 0.14-0.83),
and 27% (0.73, 0.55-0.99) when compared with HCQ. The corre-
sponding reduction rate of any AEs when compared with HCQ
plus azithromycin (HCQ+AZT) was 69% (0.31, 0.12- 0.83) for
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Table 1. Continued from previous page.      
Study               Location           Design             Age       Follow-            Total          Randomized treatments                                           Main primary                                   Sponsorship          Risk of
                                                                        (mean,       up         participants     in each group,                                                           endpoints                                                                          bias
                                                                        years)     (days)       (proportion     dosing information                                                                                                                                             (Rob2)
                                                                                                              of men)        
Miller                         US                Open-label,              60                28               26 (46.2%)         250 mg of auxora at 24 h and subsequent                          Safety and tolerability                              CalciMedica                 Some 
et al.26                                             RCT phase 2                                                                                  doses of 200 mg at 48 h;                                                          of auxora at 28-day.                                                                        concerns
                                                                                                                                                                  Standard of care
RECOVERY28             UK                       RCT                     59                28             6,425 (71.9%)      Dexamethasone 6mg/d orally or intravenously;                28-d mortality.                                             UK                               Low risk 
                                                                                                                                                                  Standard care                                                                                                                                                   Government               of bias
CAPE COVID29       France                   RCT                    62.2              21              149 (69.8%)        Continuous intravenous infusion of hydrocortisone       Treatment failure on day 21                    French Ministry       Low risk 
                                                                                                                                                                  200 mg for 7 days and decrease to 100 mg                         (death or persistence                             of Health                    of bias
                                                                                                                                                                  for 4 days and 50 mg for 3 days;                                            dependence of
                                                                                                                                                                  Placebo                                                                                       mechanical ventilation 
                                                                                                                                                                                                                                                                        or high-flow oxygen therapy).                 
CoDex27                   Brazil              Open-label,              62                28              256 (63.3%)        Dexamethasone 20 mg/d intravenously x                           Ventilator free days                                  Hospital                     Low risk 
                                                                 RCT                                                                                         5 d and then 10 mg/d intravenously x 5 d;                                                                                                  Sirio-libanes               of bias
                                                                                                                                                                  Standard care
REMAP-CAP6       Australia,          Open-label,              59                28              197 (71.4%)        Hydrocortisone 50 mg every 6 h x 7 d;                                 Composite of hospital mortality            MJM Bonten             Low risk 
                                Canada,                   RCT                                                                                         Standard care                                                                            and ICU organ support-free                   UMC Utrecht              of bias
                              European                                                                                                                                                                                                                        days to 21 d.
                             Union, New
                               Zealand, 
                                 UK, US
DEXA-                       Spain              Open-label,              62                28               19 (57.1%)         Dexamethasone 20 mg/d intravenously x                           60-d mortality.                                             Dr. Negrin                 Low risk 
COVID-196                                                          RCT                                                                                         5 d and then 10mg/d intravenously x 5d;                                                                                                     University                   of bias
                                                                                                                                                                  Standard care                                                                                                                                                   Hospital                             
Covid                    Denmark             Blinded,                60.5              28              29 (79.05%)        Hydrocortisone 200mg/d intravenously x                           Days alive without live                             Department              Low risk 
Steroid6                                                  RCT                                                                                         7 d [continuous or bolus dosing (50 mg) every 6h];       support at 28 d.                                          of Intensive Care       of bias
                                                                                                                                                                  Standard care                                                                                                                                                   Rigshospitalet 
                                                                                                                                                                                                                                                                                                                                               Denmark
Steroids-                 China                    RCT                    64.5              30               47 (74.5%)         Methylprednisolone 40mg intravenously                           Lower lung injury score                           Pekin Union             Hight risk 
SARI6                                                                                                                                                        every 12h x 5 d;                                                                          at 7 d and 14 d.                                            Medical College         of bias
                                                                                                                                                                  Standard care                                                                                                                                                   Hospital
aDisease severity scale was defined as follow: 6-point, death; 5 points, hospitalization plus extracorporeal membrane oxygenation (ECMO) or invasive mechanical ventilation; 4 points, hospitalization plus noninvasive ventilation or high-flow supplemental oxygen; 3 points, hospitalization
plus supplemental oxygen (not high-flow or noninvasive ventilation); 2 points, hospitalization plus supplemental oxygen; 1 point, hospital discharge; bmedian age; cproportion of patients aged 65 years or older; RCT: randomized controlled trials; CIFMS: Chinese Academy of Medical Sciences
Innovation Fund for Medical Sciences; NDCD: new drug creation and development; CAMSEP: Chinese academy of Medical Sciences Emergency Project of Covid-19; NKRDPC: national key research and development program of China; BSTP: the Beijing science and technology project; IDSG:
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dexamethasone, 65% (0.35, 0.13-0.96) for arbidol, 54% (0.46,
0.24-0.86) for a low dose of HCQ (450 mg), and 32% (0.68, 0.47-
0.97) for standard care (Supplementary Table 4). 
Serious adverse events
A total of 598 serious adverse events were recorded from 15
RCTs involving 19 comparisons of 11 different treatments. A com-
bination of lopinavir/ritonavir and ribavirin was associated with a
risk reduction for any severe AEs with a probability 86% (P-score
0.86). Compared to standard care, remdesivir for both 5 and 10
days, lopinavir/ritonavir, and dexamethasone reduced the risk of
any severe AEs by 52% (0.48, 0.34-0.67), 24% (0.77, 0.63-0.92),
40% (0.60, 0.37-0.98), and 50% (0.50, 0.25-0.98) respectively
(Figure 3). Moreover, we found that the short exposition of remde-
sivir (5 days) reduced the risk of any severe AEs by 37% (0.63,
0.46-0.85) compared with the long exposition (10 days), and by
50% (0.50, 0.35-0.71) compared to methylprednisolone
(Supplementary Table 5).
Sensitivity, heterogeneity, and consistency
In sensitivity analysis, after considering any systematic corti-
costeroids as a single treatment, ruxolitinib (P-score 0.82)
remained the best option to reduce all-cause mortality 28 days after
randomization (Supplementary Table 6). Compared with standard
care, both 5-day and 10-day courses of remdesivir and routine cor-
ticosteroids were associated with lower 28-day all-cause mortality.
The specific relative reductions were as follows: for 5-day remde-
sivir, 52% reduction (0.48, 0.23-0.98); for 10-day remdesivir, 34%
reduction (0.66, 0.45-0.96); and for routine corticosteroids, 15%
reduction (0.85, 0.76-0.95). In addition, a low dose of HCQ
reduced by 72% (0.28, 0.09-0.80) the risk of death compared with
a high dose of HCQ.
No global heterogeneity was found for mortality (Cochran’s Q
7.72; p=0.36; t2=0.0; I2=9.4% [0%-70.6%]). For adverse event and
clinical improvement, global heterogeneity was significant (17.4;
p=0.043; t2=0.02; I2=48.2% [0.0%-75.0%] and 17.2; p=0.028;
t2=0.010; I2=53.4% [1.0%-78.1%] respectively), mainly due to
significant between-design heterogeneity (AEs and clinical
improvement). These finding were supported by the heat plot dis-
played in the Supplementary Figures 5 to 9). 
Discussion
One month after our previously published report,7, we per-
formed an update network meta-analysis of 25 RCTs that included
11,597 patients randomly assigned to 17 different treatments
against SARS-CoV-2. Compared to standard care, the administra-
tion of a 10-day course of remdesivir was associated with a lower
all-cause mortality and serious adverse event at 28 day, and a high-
er rate of clinical improvement. In addition, we found that com-
pared to high dose, low dose of HCQ was associated with a lower
28-day mortality. Convalescent plasma was associated with a high
rate of viral clearance, and dexamethasone and lopinavir/ritonavir
were associated with a low risk of serious adverse event. 
The WHO Rapid Evidence Appraisal for COVID-19 Therapies
(REACT) Working Group6 reported the benefit of administration
of systemic corticosteroids to reduce 28-day mortality by 34% in
COVID-19 patients compared to standard care. However, when
corticosteroid types were considered, a benefit was only observed
in patients receiving dexamethasone (0.64, 0.50-0.82). These find-
ings were based on a fixed effect-model, while those on the ran-
dom-effect model were not significant. After considering all avail-
able option for COVID-19 management, there was no evidence of
a benefit of dexamethasone or hydrocortisone or methylpred-
nisolone in reducing 28-day all-cause mortality (Supplementary
Table 6). However, all corticosteroids were considered as a single
treatment, we found that administration of systematic corticos-
teroids reduced 28-day mortality by 15%. This is similar in magni-
tude to the data reported in the RECOVERY trial28 in which dex-
amethasone reduced by 17% (0.83, 0.75-0.93) 28-day mortality
compared to standard care. 
Most of the treatments being compared were tested in hospital-
ized patient with severe condition. At the time these trials were
designed, little was known about the physiopathology of COVID-
19. To date, we believed that the optimal management of COVID-
19 could take in to account the stage of the disease. First, we found
that the use of convalescent plasma increases viral clearance, sug-
gesting that convalescent plasma may be beneficial for the early
phase of the disease. Second, given the results of a 10-day course
of remdesivir on 28-day all-cause mortality and clinical improve-
ment rate, in the absence of contraindication, its use could benefit
patient before the onset of a respiratory failure. Finally, as pro-
posed by the WHO Rapid Evidence Appraisal for COVID-19
Therapies (REACT) Working Group, in the absence of compelling
contraindication, a corticosteroid regimen should be a component
of standard care for critically ill patients with COVID-19.
The place of hydroxychloroquine in the therapeutic panel in
patients with COVID-19 is unclear. We found that low dose of
hydroxychloroquine (400 mg/d for 5 days) was associated with
lower 28-day all-cause mortality and serious adverse event as com-
pared to high dose, but with no benefit compared to usual care.
These findings are in line with a recent systematic review of 32
studies (29,192 participants) on the efficacy and safety of chloro-
quine/hydroxychloroquine for COVID-19. The authors concluded
that the available evidence from biased, moderate-risk studies did
not suggest any benefit of CQ/HCQ in terms of mortality in hospi-
talized patients with COVID-19 compared to standard care.37
Nevertheless, available date on the efficacy of HCQ are conflict-
ing.32-36 While Million et al.3 shows that patients who received
HCQ had a 68% (0.32, 0.19-0.52) reduction in the risk of death
compared to those without HCQ, Singh4 and Fiolet5 indicate the
complete opposite with an increase in mortality for patients treated
by HCQ. Furthermore, the Canadian trial on the prophylactic role
of HCQ shows that hydroxychloroquine did not prevent illness
compatible with COVID-19 or confirmed infection when used as
postexposure prophylaxis within 4 days after exposure to COVID-
19.38
Although our study provides the most recent evidence to date
on the comparative efficacy and safety of available treatments
against SARS-CoV-2, these findings should be interpreted with
caution. We are aware that the majority of pharmacological drugs
classified as the best options for clinical improvement, all-cause
mortality or safety concerns have only been tested once, and fur-
ther data are needed to replicate these results. To date several trials
registered in ClinicalTrials.gov databases are ongoing, and results
are expected in the coming months. When all ongoing trials are
published, an update of this work will be necessary to draw defin-
itive conclusions about the efficacy and safety of the treatments
tested against SAR-CoV-2.
Limitations
This study has several limitations. First, the small number of
RCTs included in the network meta-analysis negating the possibil-
ity of performing subgroup analyzes according to studies charac-
teristics (design, follow-up, sample size, endpoint assessment,










points used to assess of efficacy and safety outcomes may poten-
tially influence the results. Third, we did not find RCT about
asymptomatic or pauci-symptomatic patients with positive SARS-
CoV-2 test, in whom the standard of care is observation and quar-
antine.38 In addition, the majority of RCT included a large number
of patients who have satisfactory clinical parameters, like SOFA 1,
oxygen saturation 97.7%,1) or those not needing oxygen supple-
mentation.28
Conclusion
In this network meta-analysis of 25 randomized trials against
COVID-19 disease, the administration of a 10-day course of
remdesivir was associated with lower 28-day all-cause mortality
and serious adverse event, and higher clinical improvement rate
compared to standard care. Colchicine and high dose of HCQ
raised more safety concerns compared to dexamethasone, arbidol,
favipiravir, low dose of HCQ (400 mg), remdesivir for both 5 and
10 days, and standard of care. As the pandemic is still ongoing,
definitive conclusion will be drawn taking into account the results
of ongoing and future studies. Nevertheless, these findings have
implications for the design and management of future COVID-19
clinical trials.
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